文献速递消化道肿瘤放疗

胃癌辅助放化疗:现状与展望

Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives.
PubMed 文献 · Clin Transl Radiat Oncol · 2018-03-13

本文综述胃癌辅助放化疗的现状与前景。全球每年新发胃癌约99万例,仅约20%可手术,术后中位生存12至20个月。研究显示术后放化疗与围手术期化疗均有生存获益,III期试验正在进行中。

要点

  • 全球每年新发胃癌约99万例,仅约20%病例可行手术切除。
  • 术后中位生存仅12至20个月,局部区域和/或转移复发常见。
  • 术后放化疗与围手术期化疗均已显示生存获益,III期对比试验进行中。

核心结论

  • 迄今证据显示术后放化疗和围手术期化疗均有生存获益,正在进行的III期试验将比较这两种模式。

研究设计与样本

  • 综述,旨在综合胃癌辅助放化疗的现有知识,并整合现代放疗技术展望其前景。

主要发现

  • 全球每年新发胃癌约99万例,手术切除是唯一可能延长生存的手段,但仅约20%病例可行手术。
  • 即使手术后,由于局部区域和/或转移复发频繁,中位生存仅限12至20个月。
  • 术后放化疗和围手术期化疗均已显示生存获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An estimated 990,000 new cases of gastric cancer are diagnosed worldwide each year. Surgical excision, the only chance for prolonged survival, is feasible in about 20% of cases. Even after surgery, the median survival is limited to 12 to 20 months due to the frequency of locoregional and/or metastatic recurrences. This led to clinical trials associating surgery with neoadjuvant or adjuvant treatments to improve tumor control and patient survival. The most studied modalities are perioperative chemotherapy and adjuvant chemoradiotherapy. To date, evidence has shown a survival benefit for postoperative chemoradiotherapy and for perioperative chemotherapy. Phase III trials are ongoing to compare these two modalities. The aim of this review is to synthesize current knowledge about adjuvant chemoradiotherapy in the management of gastric adenocarcinoma, and to consider its prospects by integrating modern radiotherapy techniques.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schernberg A, Rivin Del Campo E, Rousseau B, et al. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clin Transl Radiat Oncol. 2018. PMID: 29928701. doi:10.1016/j.ctro.2018.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。